For the identification of FDA-approved D2R antagonists for anti-dengue treatment, the antiemetic MCP was individually investigated in this study because it has been used not only for D2R antagonism but also for symptomatic medication, including persisting nausea and vomiting, during the onset of dengue fever (Marra et al., 2011). The gene discussed is DRD2; the disease is dengue disease.